Participations à des congrès et colloques internationaux (81)
  1. 5. Guilao, M. G. M., Wauthoz, N., Bah, T. V. B. T., Atchade, C., Traore, T., Souard, F., Sombié, C., Semdé, R., & Balde, E. S. (2025). Physicochemical and rheological characterization of new local excipient powders as adjuvant for oral formulations. Paper session presented at Forum des sciences pharmaceutiques, BSPS (22: 31st March-1st April 2025: La-roche-en-Ardenne, Belgium).
  2. 6. Abidli, I., Burtea, C., Laurent, S., Amighi, K., Wauthoz, N., & Vanderbist, F. (2025). Assessment of antibiofilm activity against Pseudomonas aeruginosa: A focus on N-acetylcysteine, lutein, and quercetin. Paper session presented at Forum of Pharmaceutical Sciences (22: 31st March to 1st April 2025: La Roche-en-Ardenne, Belgium).
  3. 7. Bui, L., Menchi, E., Blockx, M.-C., Olivier, D., Delporte, C., Amighi, K., & Wauthoz, N. (2025). PHARMACOKINETIC EVALUATION OF CONTROLLED RELEASE DRY POWDERS FOR INHALATION BASED ON BUDESONIDE IN RATS. Paper session presented at Forum des sciences pharmaceutiques (22: 31 March-1 april 2025: La-roche-en-ardenne, Belgium).
  4. 8. Abidli, I., Burtea, C., Laurent, S., Amighi, K., Wauthoz, N., & Vanderbist, F. (2025). ASSESSMENT OF ANTIBIOFILM ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA: A FOCUS ON N-ACETYLCYSTEINE, LUTEIN, AND QUERCETIN. Abstract session presented at
  5. 9. Abidli, I., Burtea, C., Laurent, S., Amighi, K., Wauthoz, N., & Vanderbist, F. (2025). Early biofilm inhibition by N-acetylcysteine and lutein against Pseudomonas aeruginosa PAO1: A potential strategy for cystic fibrosis adjunctive therapy. Paper session presented at European Cystic Fibrosis Conference (48: 4-7th June 2025: Milan (Italy)).
  6. 10. Wauthoz, N., Rosiere, R., & Amighi, K. (2024). Inhaled chemotherapy as a new modality to increase immunotherapy response in lung cancer therapy. Paper session presented at Rescon summit Europe (2024: 26-28-06-2024: Barcelona).
  7. 11. Bui, L., Menchi, E., Hennia, I., Amighi, K., & Wauthoz, N. (2024). Development of innovative controlled released dry powders for inhalation based on budesonide for a once daily administration. In Abstracts from The Aerosol Society Drug Delivery to the Lungs 34: Edinburgh International Conference Centre Edinburgh, Scotland, UK December 6–8, 2023: Vol. 37 United Kingdom: Mary Ann Liebert, Inc., publishers.
  8. 12. Wauthoz, N., Rosiere, R., & Amighi, K. (2024). New Inhaled Therapies to Increase the Immunotherapy Response in Lung Cancer Therapy. Paper session presented at Annual International Symposium of Drug Delivery Systems (11th: 22-24-05-2024: Osaka).
  9. 13. Wauthoz, N. (2024). Optimisation of Nanobodies for Astma. Paper session presented at Formulation & Delivery 2024 (25 & 26-04-2024: london).
  10. 14. Bui, L., Menchi, E., Blockx, M.-C., Olivier, D., Delporte, C., Amighi, K., & Wauthoz, N. (2024). Pharmacokinetic evaluation of controlled release dry powders for inhalation based on budesonide in healthy rats. Paper session presented at Drug Delivery to the lungs (2024: 11-14th December 2024: edinburg).
  11. 15. Bui, L., Menchi, E., Hennia, I., Amighi, K., & Wauthoz, N. (2024). Development of innovative controlled released dry powders for inhalation based on budesonide for a once daily administration. Poster présenté à la conférence Drug Delivery to the Lungs (34: 2023/12/06 - 2023/12/08: Edinburgh, Scottland).
  12. 16. Wauthoz, N., Gevenois, P., Menchi, E., Lambot, C., Sebti, T., & Amighi, K. (2023). Evaluation of the efficacy of an innovative triparatopic anti-IL-13 VhH in a murine preclinical model of respiratory inflammation. Paper session presented at International Society For Aerosols in Medecine (2023: 26-30th August 2023: Saarbrücken).
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Suivant >>